Medtronic wins FDA clearance for LigaSure on Hugo robot

Medtronic received clearance from the US Food and Drug Administration on 19 September 2026 for its LigaSure vessel-sealing device on the Hugo robotic surgery system.

The regulatory decision permits LigaSure to be deployed on the Hugo platform for soft-tissue procedures across US hospitals and surgical centers. This configuration combines a widely used vessel-sealing instrument directly into the company's robotic-assisted surgery system for general surgery applications.

The company operates with a US$118.7 billion scale in medical equipment, providing an extensive installed base where additions to Hugo can integrate into current surgical workflows. Connecting a familiar energy tool to the robotic platform helps expand its potential reach against competitors like Intuitive Surgical and Johnson & Johnson.

Market analysts note that commercial execution remains a key question for the rollout. The clearance does not establish how fast healthcare facilities will adopt Hugo for varied soft-tissue cases, nor its final impact on operating margins as the group balances development spending, training and pricing.